Nevro/NVRO

$12.34

0.16%
-
1D1W1MYTD1YMAX

About Nevro

Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Ticker

NVRO

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

D. Keith Grossman

Employees

1,215

Headquarters

Redwood city, United States

Nevro Metrics

BasicAdvanced
$450.81M
Market cap
-
P/E ratio
-$2.57
EPS
0.92
Beta
-
Dividend rate
$450.81M
0.9165
$39.68
$12.15
452.01K
6.368
4.944
72.139
72.139
-14.9%
-29.89%
-17.15%
1.06
1.524
1.981
4.63%
-5,699.73%
5.5%

What the Analysts think about Nevro

Analyst Ratings

Majority rating from 18 analysts.
Hold

Price Targets

Average projection from 15 analysts.
41.57% upside
High $40.00
Low $14.00
$12.34
Current price
$17.47
Average price target

Nevro Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-7.66% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$116.1M
11.85%
Net income
$-8.9M
-61.97%
Profit margin
-7.66%
-66.02%

Nevro Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 48.9%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.98
-$0.69
-$0.65
-$0.25
-
Expected
-$1.04
-$0.69
-$0.77
-$0.49
-$1.05
Surprise
-5.96%
-0.11%
-15.44%
-48.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nevro stock?

Nevro (NVRO) has a market cap of $450.81M as of April 19, 2024.

What is the P/E ratio for Nevro stock?

The price to earnings (P/E) ratio for Nevro (NVRO) stock is 0 as of April 19, 2024.

Does Nevro stock pay dividends?

No, Nevro (NVRO) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Nevro dividend payment date?

Nevro (NVRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Nevro?

Nevro (NVRO) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Nevro stock price target?

The target price for Nevro (NVRO) stock is $17.47, which is 43.2% above the current price of $12.2. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nevro stock

Buy or sell Nevro stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing